# Efficacy and Safety of Alogliptin vs. Acarbose in Chinese Type 2 Diabetes Mellitus (T2DM) Patients With High CV Risk or CHD Treated With Aspirin and Inadequately Controlled With Metformin Monotherapy or Drug Naive

Study · id `cardio:ct-nct03794336` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03794336](<https://clinicaltrials.gov/study/NCT03794336>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03794336

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1293 participants.

## Technical summary

Registry record NCT03794336. Randomized; no masking; primary purpose treatment. Start 2019-06-29 (actual); primary completion 2020-12-14 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 1293 participants (enrolled count; ClinicalTrials.gov record NCT03794336, source copy `cardio:ctgov-nct03794336-2022-04-25`, retrieved 2026-10-26)
- Started: 2019-06-29 (actual) (ClinicalTrials.gov record NCT03794336, source copy `cardio:ctgov-nct03794336-2022-04-25`, retrieved 2026-10-26)
- Primary completion: 2020-12-14 (actual) (ClinicalTrials.gov record NCT03794336, source copy `cardio:ctgov-nct03794336-2022-04-25`, retrieved 2026-10-26)
- Completion: 2020-12-14 (actual) (ClinicalTrials.gov record NCT03794336, source copy `cardio:ctgov-nct03794336-2022-04-25`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT03794336, source copy `cardio:ctgov-nct03794336-2022-04-25`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03794336-2022-04-25`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of Alogliptin vs. Acarbose in Chinese Type 2 Diabetes Mellitus (T2DM) Patients With High CV Risk or CHD Treated With Aspirin and Inadequately Controlled With Metformin Monotherapy or Drug Naive
- Acronym: ACADEMIC
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): Alogliptin
- Intervention (Drug): Acarbose
- Intervention (Drug): Metformin
- Intervention (Drug): Aspirin
- Lead sponsor: Sanofi
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record: Aspirin (`core:aspirin`)
- Registry lists this organization as the lead sponsor: Sanofi (`cardio:org-sanofi`)

## Provenance

Content hash: 146352b818fe03137f75ab3147f5f44b2a45201df1053814bd3b9c79f3b23c3c
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
